Remove Download Remove HIV Treatment and Prevention Agents Remove Vaccines
article thumbnail

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents. Utilizing colony-stimulating factors (CSFs) decreases the incidence of severe FN.

article thumbnail

Oral COVID Agents

Pharmacy Friday Pearls

Download PDF. 18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98